Form 4: Mirum CEO Exercises, Sells 40,000 Shares

Mirum Pharmaceuticals CEO Christopher Peetz exercised and sold 40,000 shares of common stock as part of a pre-arranged trading plan.

Summary

• Christopher Peetz, CEO and Director of Mirum Pharmaceuticals, Inc. (MIRM), exercised employee stock options to acquire 40,000 shares of common stock at an exercise price of $2.936 per share.
• Concurrently, Mr. Peetz sold 40,000 shares of common stock at a weighted average sale price of $55.251 per share, with prices ranging from $55.25 to $55.485.
• The transactions were conducted on August 7, 2025, and were executed pursuant to a Rule 10b5-1 trading plan adopted on November 22, 2024.
• Following these transactions, Mr. Peetz directly holds 138,641 shares of common stock and indirectly holds 208,570 shares through The Peetz Family Trust.
• Mr. Peetz also retains 198,487 employee stock options after the exercise.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While an insider sale can sometimes be viewed negatively, the fact that it was conducted under a pre-arranged 10b5-1 plan makes it a routine, expected event rather than a signal of immediate concern about the company's prospects.

Positives

• The exercise of stock options indicates the CEO's engagement with the company's equity compensation plan.
• The sale was conducted under a pre-arranged Rule 10b5-1 plan, which suggests a structured and pre-determined transaction rather than an immediate reaction to market conditions.

Negatives

• The sale of 40,000 shares by the CEO reduces his direct beneficial ownership, which could be perceived by some investors as a lack of confidence, although it was pre-planned.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This filing details an individual insider transaction and does not provide broader insights into industry trends or competitive landscape within the pharmaceutical sector. It reflects a routine compensation-related transaction for a senior executive.

Stakeholder Impact

• Shareholders: The sale by a key executive, even if pre-planned, might lead to minor short-term speculation, but the impact is generally limited given the routine nature of 10b5-1 sales.

Key Dates

Recommendation

This Form 4 filing details a routine, pre-planned insider transaction (exercise and sale of shares under a 10b5-1 plan) by the CEO. It does not provide new information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Such transactions are common for executives managing their personal portfolios and compensation. Therefore, a 'hold' recommendation is appropriate as this filing alone does not present a compelling reason to buy or sell the stock.

Keywords

Mirum Pharmaceuticals, MIRM, Christopher Peetz, Insider Trading, Stock Option Exercise, Share Sale, Rule 10b5-1 Plan, CEO, Pharmaceuticals